Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
2015-005195-22Phase 3
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of salmonella typhi capsular polysaccharide vaccine in typhoid fever, sponsored by Sanofi. Primary endpoints: Seroconversion rate (≥4-fold rise in Vi antibody titers) and Safety profile up to 28 days.
02
Drugs
salmonella typhi capsular polysaccharide vaccine
03
Conditions
typhoid fever
Beyond the preview
Go deeper on 2015-005195-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005195-22.